Wednesday, May 15, 2013

Summary of inappropriate image manipulation by Shokei Kim-Mitsuyama's group.

PLoS One. 2012;7(6):e39162.
Calcium channel blockers, more than diuretics, enhance vascular protective effects of angiotensin receptor blockers in salt-loaded hypertensive rats.
Corresponding author: Shokei Kim-Mitsuyama
Lanes 2, 3 and 4 (Ol, Az, and Hy) of tubulin blots in Fig.4 (A) and Fig.4(B) are similar to lanes 1, 2, and 3 (Ve, Ol, and Az) of tubulin blots in Fig.4(C), and lanes 5, 6 and 7 (Ol+Ax, Ol+Hy, and WKY) of tubulin blots in Fig.4(A) and Fig.4(B) are similar to lanes 4, 5, and 6 (Hy, Ol+Az, and Ol+Hy) of tubulin blots in Fig.4(C). There is discontinuity between lanes 4 and 5 of tubulin blots in Fig.4(A) and Fig.4(B) between lanes 3 and 4 of tubulin blots in Fig.4(C), which indicates deliberate image manipulation. Lanes 2, 3, 4, 5, 6, and 7 (Ol, Az, Hy, Ol+Ax, Ol+Hy, and WKY) of tubulin blots in Fig.4(A) and Fig.4(B) are similar to lanes 1, 2, 3, 4, 5, and 6 (Ve, Ol, Az, Hy, Ol+Az, and Ol+Hy) of tubulin blots in Fig.4(D) and Fig.5(B).

Circulation. 2006 Mar 14;113(10):1353-60.
Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications.
Corresponding author: Hui Y. Lan
"GAPDH" in Fig.3(B) is similar to "GAPDH" in Fig.4(B).

J Pharmacol Sci. 2005 Aug;98(4):372-9.
Beneficial effect of candesartan on rat diastolic heart failure.
Corresponding author: Shokei Kim-Mitsuyama
Fig.4 - "BNP" is similar to "MCP-1". 

Hypertens Res. 2005 May;28(5):447-55.
Excess aldosterone under normal salt diet induces cardiac hypertrophy and infiltration via oxidative stress.
Corresponding author: Shokei Kim-Mitsuyama
Fig.2B - "Con" is similar to "ALD/Spi ".

Circ Res. 2003 Oct 31;93(9):874-83.
Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling.
Corresponding author: Shokei Kim-Mitsuyama
Fig.4A - "Wild" image is similar to  "ASK1 -/-". 

J Am Soc Nephrol. 2003 Mar;14(3):584-92.
Differential contribution of three mitogen-activated protein kinases to PDGF-BB-induced mesangial cell proliferation and gene expression.
Corresponding author: Shokei Kim-Mitsuyama
Fig.1C - Image of 3 lanes of "ERK" is similar to  that of "p38".

Hypertension. 2000 Oct;36(4):511-6.
Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertrophy in hypertensive rats.
Corresponding author: Shokei Kim-Mitsuyama
Fig.2 - The left lane of "ERK-Lo" in the Fig.2 is similar to  the right lane of "ERK-W" in Fig.4(B). 

Circ Res. 1998 Oct 5;83(7):752-60.
Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension.
Corresponding author: Shokei Kim-Mitsuyama,  Co-author: Shinya Yamanaka
Fig.1C - The lane of  "5min" is similar to  the horizontally flipped image of "3h" lane. 

Hypertension. 1998 Jan;31(1):50-6.
Cardiac mitogen-activated protein kinase activities are chronically increased in stroke-prone hypertensive rats.
Corresponding author: Shokei Kim-Mitsuyama, Co-author: Shinya Yamanaka
Fig.5 - The left lane and right lane of "S (SHRSP)" of "24 wk" are similar.

Kyoto Heart Study

Eur Heart J. 2009 Oct;30(20):2461-9. doi: 10.1093/eurheartj/ehp363. Epub 2009 Aug 31.

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study.

Takahisa Sawada1*, Hiroyuki Yamada1, Bjo¨ rn Dahlo¨ f 2, and Hiroaki Matsubara1 for the KYOTO HEART Study Group 
1 Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kajiicho 465, Kamigyoku, Kyoto 602-8566, Japan; and 
2 Department of Medicine, Sahlgrenska University Hospital/ O¨ stra, Go¨ teborg, Sweden


"This article has been retracted by the journal. Critical problems existed with some of the data reported in the above paper. The editors of the European Heart Journal hereby retract this paper and discourage citations of it."

Conflict of interest: the sponsor had no role in study design, data
collection, data analysis, data interpretation, or writing of the report.
The executive committee had full access to all the data at the end
of the study, and has final responsibility for the decision to submit
for publication.

Endpoint committee
Jitsuo Higaki, Department of Integrated Medicine and Informatics,
Ehime University Graduate School of Medicine; Shokei Kim-
Mitsuyama, Department of Pharmacology and Molecular Therapeutics,
Kumamoto University School of Medicine; Toshihiro
Ichiki, Department of Cardiovascular Medicine, Kyushu University
School of Medicine, Japan.

J Hum Hypertens. 2009 Mar;23(3):188-95. doi: 10.1038/jhh.2008.116. Epub 2008 Sep 18.

Rationale and design of the KYOTO HEART studyeffects of valsartan on morbidity and mortality in uncontrolledhypertensive patients with high risk of cardiovascular events.

Sawada T, Takahashi T, Yamada H, Dahlöf B, Matsubara H; KYOTO HEART Study Group.

Collaborators (56)
Matsubara H, Dahlöf B, Sawada T, Shirayama T, Mori Y, Okigaki M, Matsumuro A, Yamada H, Tsutsumi Y, Matoba M, Takahashi T,Shiraishi H, Ikeda K, Nakamura T, Yamada T, Hirano S, Azuma A, Kimura S, Sasaki S, Shiga K, Maki K, Furukawa K, Okuda S, Kajita Y,Nishio M, Kohno Y, Kitamura M, Nishida K, Yamahara Y, Nakamura T, Sawada S, Sakai R, Kuriyama T, Miyanaga H, Kitani T, Haruyama H, Nishio A, Kinoshita N, Inagaki S, Sugihara H, Katamura M, Hachiya T, Kato S, Ohtsuki K, Higaki J, Kim-Mitsuyama S, Ichiki T, Kitakaze M, Sugiura T, Rakugi H, Yagi K, Kanda K, Sakakura C, Shirahasi N , Miki M, Toyoda S.


Department of Cardiovascular Medicine, Kyoto Prefectural University School of Medicine, Kyoto, Japan.

論文の本文中に、ノバルティスファーマ社員の白橋伸雄氏がStatistics analysis organisationとして統計解析に関与していたことが記載されている。しかし、所属は大阪市立大学となっており、ノバルティスファーマ社員であることが隠蔽されている。

Statistical analysis organization
K Yagi, Louis Pasteur Center for Medical Research,
Kyoto, Japan; Nobuo Shirahashi, Department of
Preventive Medicine and Environmental Health,
Osaka City University Medical School, Osaka,

Department of Pharmacology and Molecular Therapeutics

DivisionIntegrated Medical and Pharmaceutical Sciences
Great DepartmentPharmacotherapeutics
ProfessorShokei Mitsuyama
kimmitsu(at mark)

No comments:

Post a Comment